SNS-314 is a synthetic small molecule Aurora kinase (AK) inhibitor with potential antineoplastic activity. Aurora kinase inhibitor SNS-314 selectively binds to and inhibits AKs A and B, which may result in the inhibition of cellular division and proliferation in tumor cells that overexpress AKs. AKs are serine-threonine kinases that play essential roles in mitotic checkpoint control during mitosis.

Seladelpar sodium salt (MBX-8025) is an orally active, potent and specific PPARδ agonist with an EC50 of 2 nM, showing more than 750-fold and 2500-fold selectivity over the PPARα and PPARγ receptors, respectively.

ReACp53 is a cell-penetrating peptide,designed to inhibit p53 amyloid formation.

MBX-4132 a trans translation inhibitor by binding to the bacterial ribosome.

KDOAM25 is a selective inihbitor of the KDM5 family histone demethylases JARID1A, JARID1B, JARID1C and JARID1D with IC50 values < 60 nM.

DBPR114 is a quinazoline-based multi-kinase inhibitor for the treatment of acute myeloid leukemia and other solid tumors.

N-Acetyl lysyltyrosylcysteine amide is a potent, reversible, specific, and non-toxic tripeptide inhibitor of myeloperoxidase (MPO). N-Acetyl lysyltyrosylcysteine amide effectively inhibits MPO generation of toxic oxidants in vivo. N-Acetyl lysyltyrosylcysteine amide reduces neuronal damage and preserves brain tissue and neurological function in the stroked brain. N-Acetyl lysyltyrosylcysteine amide inhibits MPO-dependent hypochlorous acid (HOCl) generation, protein nitration, and LDL oxidation.

KY-04031 is a PAK4 inhibitor with IC50 of 0.79 uM, a basic building block in designing novel imidazo[4,5-b]pyridine-based PAK4 inhibitors..

Naxillin is the first non-auxin-like molecule that promotes root branching, activates a subset of auxin-induced transcripts, including AUX/IAA, SAUR and PIN families; induces auxin response in the basal meristem; represents a valuable tool to further decipher the molecular networks involved in lateral root branching.

DFP00173 (DFP-00173) is a potent and selective aquaporin-3 (AQP3) inhibitor, inhibits glycerol permeability in erythrocytes with IC50 of 0.2 uM..

AG-636 is an orally available inhibitor of dihydroorotate dehydrogenase (DHODH) with potential antineoplastic activity.

ON1231320 is a potent selective inhibitor of Polo like kinase 2 (PLK2).

Abiraterone acetate is an FDA approved drug, and is an orally active acetate ester of the steroidal compound abiraterone with antiandrogen activity. Abiraterone acetate was approved by the U.S. Food and Drug Administration (FDA) in April 2011. Abiraterone inhibits the enzymatic activity of steroid 17alpha-monooxygenase (17alpha-hydrolase/C17,20 lyase complex), a member of the cytochrome p450 family that catalyzes the 17alpha-hydroxylation of steroid intermediates involved in testosterone synthesis. Administration of this agent may suppress testosterone production by both the testes and the adrenals to castrate-range levels. FDA Approval this drug in May 2011.

SBI-477 is a chemical probe that coordinately inhibits triacylglyceride (TAG) synthesis and enhances basal glucose uptake in human skeletal myocytes with EC50 of 100 nM and 1 uM, respectively.

AZ10606120 is a potent, specific P2X7 receptor antagonist with Kd of 1.4 and 19 nM at human and rat P2X7 receptors respectively.

GLS4 (Morphothiadin) is a potent inhibitor of HBV capsid assembly, inhibits HBV replication (EC50=62.24 nM) and reduces HBV-DNA levels in HepG.2.2.15 cells (IC50=14 nM), shows efficacy against ADV-resistant HBV mutations.

Polymyxin B is an antibiotic primarily used for resistant gram-negative infections.

DM-PIT-1 is a specific PIP3 antagonist that disrupts PIP3/Akt PH domain, PIP3/PDK1 PH domain, and PIP3/GRP1 PH domain with IC50 of 27.1 uM, 80.5 uM, and 35.5 uM, respectively.

Thr-Asp-F-amidine (TDFA) is a highly potent, selective PAD4 (protein arginine deiminase 4) inhibitor with IC50 of 2.3 uM, displays ≥15-fold selectivity for PAD4 versus PAD1 and ≥50-fold versus PADs 2 and 3.

Apomorphine hydrochloride hemihydrate is a non-selective dopamine agonist which activates both D1-likeand D2-like receptors, with some preference for the latter subtypes..

Fibrinopeptide B, human TFA (FPB,human TFA), human is a 14-aa peptide, released from the amino-terminus of β-chains of fibrinogen by thrombin.

BMS-986187 is a novel potent, positive allosteric modulator of δ-opioid receptor with EC50 of 30 nM, 100-fold selectivity over μ-opioid receptor..

A potent and efficacious hERG channel activator steeply potentiates current amplitudes more than 10-fold with EC50 of 0.5 uM.

TM5007 is a poent inhibitor plasminogen activator inhibitor-1 (PAI-1) with IC50 of 29 uM, exhibits no inhibitory activity against any of the closely related serpins or serine proteases at 250 uM. .

A non-peptide small molecule agonist of the PTH1 receptor, activates both the cAMP and calcium signaling pathways..

NPY5RA972 is a neuropeptide Y Y5 antagonist.

RH01687 is a small molecule that protect pancreatic β cells against endoplasmic reticulum stress-induced cell death.

LP99 is the first potent and selective BRD7/9 bromodomain inhibitor with Kd of 99 nM for BRD9.

DCN10809, also known as Paclitaxel succinate NHS ester, is a paclitaxel derivative with a succinic acid linker, in which the carboxy group is activated with an NHS ester. The NHS ester group is highly reactive to amino group or hydroxy group, and can be used to conjugate with other molecules such as peptides, proteins, antibodies or enzymes, or polymers. Paclitaxel-Succinic acid is a useful agent to make Paclitaxel-conjugate for drug delivery, nanodrug research.

Azvudine (RO 0622) is a potent HCV NS5B RNA polymerase inhibitor, inhibits HCV replication in the replicon system with IC50 of 24 nM; inhibits RNA synthesis by HCV polymerases from either HCV genotypes 1a and 1b or containing S96T or S282T point mutations (IC50=10-100 nM).